Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Convertible Debt (2016 - 2023)

Historic Convertible Debt for Protalix BioTherapeutics (PLX) over the last 11 years, with Q4 2023 value amounting to $20.4 million.

  • Protalix BioTherapeutics' Convertible Debt fell 2755.53% to $20.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $20.4 million, marking a year-over-year decrease of 2755.53%. This contributed to the annual value of $20.4 million for FY2023, which is 2755.53% down from last year.
  • According to the latest figures from Q4 2023, Protalix BioTherapeutics' Convertible Debt is $20.4 million, which was down 2755.53% from $20.1 million recorded in Q2 2023.
  • In the past 5 years, Protalix BioTherapeutics' Convertible Debt registered a high of $53.5 million during Q3 2020, and its lowest value of $20.1 million during Q2 2023.
  • For the 5-year period, Protalix BioTherapeutics' Convertible Debt averaged around $37.1 million, with its median value being $28.2 million (2022).
  • In the last 5 years, Protalix BioTherapeutics' Convertible Debt surged by 666.23% in 2020 and then plummeted by 4801.23% in 2021.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Convertible Debt stood at $51.0 million in 2019, then rose by 5.0% to $53.5 million in 2020, then crashed by 47.88% to $27.9 million in 2021, then rose by 1.08% to $28.2 million in 2022, then dropped by 27.56% to $20.4 million in 2023.
  • Its Convertible Debt stands at $20.4 million for Q4 2023, versus $20.1 million for Q2 2023 and $28.3 million for Q1 2023.